Growth Factor Concentrate (GFC) for the Management of Osteoarthritis of the Knee: A Systematic Review.
Autologous blood
Autologous blood-derived biologics
GFC
Growth factor concentrate
Knee osteoarthritis
Orthobiologics
Ossinext
PROMs
Patient-reported outcome measures
Regenerative medicine
Journal
Indian journal of orthopaedics
ISSN: 0019-5413
Titre abrégé: Indian J Orthop
Pays: Switzerland
ID NLM: 0137736
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
27
03
2024
accepted:
24
04
2024
pmc-release:
09
05
2025
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
1
7
2024
Statut:
epublish
Résumé
The knee is the most commonly affected joint in osteoarthritis (OA), affecting millions of people worldwide. Knee OA significantly impacts the activities of daily living (ADL) along with affecting overall quality of life of patients (QoL), thereby leading to substantial socio-economic burden. Conservative therapies are prioritized, resorting to surgery only when needed. However, these traditional approaches have limitations. Regenerative medicine, involving the use of orthobiologics, including autologous peripheral blood-derived orthobiologics such as growth factor concentrate (GFC), has evolved and shown potential for managing knee OA. The primary goal of this review is to summarize the results of in vitro, preclinical and clinical studies involving GFC for the management of knee OA. Multiple databases (PubMed, Scopus, Google Scholar, Web of Science and Embase) were searched applying terms for the intervention 'GFC' and treatment 'knee OA' for the studies published in the English language to March 10, 2024. Only three clinical studies met our pre-defined criteria and were included in this review. Intra-articular administration of GFC is safe and potentially efficacious to manage OA of the knee. More, adequately powered, multi-center, prospective, RCTs are warranted to demonstrate the long-term effectiveness of GFC in patients suffering from mild-to-moderate knee OA and to justify its routine clinical use. Further studies evaluating the efficacy of GFC compared to other orthobiologics are also required to allow physicians/surgeons to choose the optimal orthobiologic for the treatment of OA of the knee.
Identifiants
pubmed: 38948375
doi: 10.1007/s43465-024-01172-w
pii: 1172
pmc: PMC11208381
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
829-834Informations de copyright
© Indian Orthopaedics Association 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no competing interests.